COVID-19 with Cardiovascular Disease: Can It Help Predict Prognosis?

Authors

  • Xiaoliang Yan, MD Department of Cardiothoracic Surgery, the First Hospital of Shanxi Medical University, Taiyuan 030001, China https://orcid.org/0000-0002-8695-9567
  • Li Jing, MD Department of Cardiothoracic Surgery, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Yongzhi Deng, MD Department of Cardiovascular Surgery, the Affiliated Cardiovascular Hospital of Shanxi Medical University, and Shanxi Cardiovascular Hospital, Taiyuan, 030024, China https://orcid.org/0000-0002-5204-3294

DOI:

https://doi.org/10.1532/hsf.3301

Keywords:

COVID-19, cardiovascular disease

Abstract

Two recent articles both found that cardiovascular disease was the major comorbidity in patients with COVID-19. Inflammation of the cardiovascular system and hypoxemia in patients with COVID-19 are the important causes of cardiovascular system dysfunction. Through detailed analyses of the cardiovascular system, clinicians may identify specific patterns of cardiovascular abnormalities. If such a model can been established, the prognosis of COVID-19 patients with cardiovascular disease may be predicted.

References

Abe H, Semba H, Takeda N. The roles of hypoxia signaling in the pathogenesis of cardiovascular diseases. J Atheroscler Thromb 2017;24:884-894.

Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis. Int J Infect Dis 2016;49:129-133.

Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003;58:686-689.

Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020;368:m1091.

Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-E9.

Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-280.e278.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Kochi AN, Tagliari AP, Forleo GB. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020;31:1003-1008.

Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: Results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007;28:1205-1210.

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-422.

Yang C, Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic-COVID-19 and cardiovascular diseases. JAMA Cardiol 2020;5:743-744.

Published

2020-11-30

How to Cite

Xiaoliang Yan, Jing, L., & Deng, Y. (2020). COVID-19 with Cardiovascular Disease: Can It Help Predict Prognosis?. The Heart Surgery Forum, 23(6), E895-E896. https://doi.org/10.1532/hsf.3301

Issue

Section

Article